KINE 201c
Alternative Names: KINE-201cLatest Information Update: 05 Feb 2024
At a glance
- Originator Kine Sciences
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Th2 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
- Discontinued Atopic dermatitis
Most Recent Events
- 05 Feb 2024 Discontinued - Preclinical for Atopic dermatitis in South Korea (unspecified route)
- 05 Feb 2024 Preclinical trials in Chronic obstructive pulmonary disease in South Korea (unspecified route) prior to February 2024 (Kine Sciences pipeline, February 2024)
- 12 May 2020 Preclinical trials in Atopic dermatitis in South Korea (unspecified route), prior to May 2020 (Kine Sciences pipeline, May 2020)